Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    20525992 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
Condition: Malignant Melanoma, Metastatic
Interventions: Biological: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF);   Biological: Ipilimumab
2 Recruiting Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Head and Neck Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Skin Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma
Interventions: Radiation: Radiation Therapy (RT);   Drug: MK-3475
3 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
4 Recruiting Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
Conditions: Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Drug: Ipilimumab;   Radiation: Whole-Brain Radiation Therapy (WBRT);   Radiation: Stereotactic Radiosurgery (SRS)
5 Unknown  A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Ipilimumab and Fotemustine

Indicates status has not been verified in more than two years